Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035344 | 0.86 | LTA4H (0.66) | LTA4HACE2GABRR1CYP1A2BLM | |
| SCHEMBL1679786 | 0.84 | LTA4H (0.68) | LTA4HACE2GABRR1CYP1A2BLM | |
| SCHEMBL20612872 | 0.81 | ACE2 (0.64) | LTA4HACE2GABRR1CYP1A2BLM | |
| SCHEMBL9001608 | 0.81 | ACE2 (0.64) | LTA4HACE2GABRR1CYP1A2BLM | |
| SCHEMBL5977939 | 0.81 | ACE2 (0.64) | LTA4HACE2GABRR1CYP1A2BLM | |
| SCHEMBL31073666 | 0.81 | ACE2 (0.64) | LTA4HACE2GABRR1CYP1A2BLM | |
| SCHEMBL9033013 | 0.80 | LTA4H (0.58) | LTA4HACE2GABRR1CYP1A2BLM | |
| SCHEMBL3811423 | 0.79 | CYP1A2 (0.67) | LTA4HACE2CYP1A2BLMFFAR4 | |
| SCHEMBL2835395 | 0.79 | CYP1A2 (0.67) | LTA4HACE2CYP1A2BLMFFAR4 | |
| SCHEMBL22190484 | 0.79 | LTA4H (0.62) | LTA4HACE2GABRR1CYP1A2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889370-B2 | Method of determining inhibitors of coagulation | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20120171697-A1 | Method of Determining Inhibitors of Coagulation | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2012-07-05 | — | — | US | disclosed |
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2091534-A1 | AZETIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-2066668-A1 | SPIROCYCLIC AZETIDINONE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF LIPID METABOLISM, PAIN, DIABETES AND OTHER DISORDERS | SCHERING CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2061792-A2 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE LIPID METABOLISM | SCHERING CORPORATION (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-1998016523-A9 | SELECTIVE FACTOR XA INHIBITORS | — | 1998-08-27 | — | — | WO | disclosed |
| EP-0846125-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1998016524-A1 | HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS | COR THERAPEUTICS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016525-A1 | SELECTIVE FACTOR Xa INHIBITORS | COR THERAPEUTICS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016547-A1 | SELECTIVE FACTOR Xa INHIBITORS | COR THERAPEUTICS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016523-A2 | SELECTIVE FACTOR XA INHIBITORS | COR THERAPEUTICS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| EP-0832102-A1 | KETOHETEROCYCLIC INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5721214-A | PEPTIDE ANTICOAGULANTS | COR THERAPEUTICS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1996040743-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040744-A1 | KETOHETEROCYCLIC INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | LTA4H 3009/4885ACE2 797/4885GABRR1 2539/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | LTA4H 1467/4885ACE2 329/4885GABRR1 2608/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | LTA4H 3270/4885ACE2 352/4885GABRR1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.